Arcus Biosciences, Inc.

Quick facts

Marketed products

• SG · Oncology
  SG is an adenosine 2A receptor antagonist that blocks immunosuppressive signaling in the tumor microenvironment to enhance anti-tumor immunity.

Phase 2 pipeline

• IPI-549 · Oncology
  PI3K/mTOR inhibitor

Phase 1 pipeline

• [14C]-etrumadenant
• AB308
• AB598
• AB680
• AB801
• m-FOLFOX-6 regimen

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Arcus Biosciences, Inc. portfolio CI brief
• Arcus Biosciences, Inc. pipeline updates RSS